However, some patients may benefit from temporary discontinuation, particularly those: In the dose-escalation phase Experiencing significant gastrointestinal symptoms With known gastroparesis or other conditions affecting gastric emptying With obesity complicated by GERD or hiatal hernia Undergoing procedures with higher aspiration risk For these higher-risk patients on once-weekly injectable semaglutide , some clinicians recommend discontinuation approximately one week (7 days) before elective surgery
Although this is consistent and mechanistically validated across different preclinical models, as reviewed in the Preclinical and clinical applications of NAD + -modulating interventions for mitochondrial homeostasis and health benefits section, the correspondence between NAD + changes and mitochondrial or metabolic alterations is more complex in human studies
First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting
For many patients who experience fatigue when starting GLP-1 therapy, symptoms often improve as the body adapts to the medication
Effervescent formulations introduce additional challenges
Do you enjoy articles like this one where we get into the specifics of one supplement or treatment modality